In addition to investigating other cancer targets, RAPT will keep working on a cancer program against general control nonderepressible 2 (GCN2), which plays a role in antitumor immunity and tumor cell survival. RAPT plans to file an IND for the drug by the end of the year. It has begun to pick up momentum since the beginning of May which is likely to continue with multiple near - and medium - term catalysts. A few key reasons Im bullish: RAPT is down 65 from its highs in January and is it not directly impacted by covid.
#Rapt therapeutics full#
I bought a full position this week at 19.50. RPT193 is designed to block the movement of type 2 helper T cells into inflamed tissues and reduce inflammation in diseases such as asthma, rhinosinusitis and atopic dermatitis. RAPT Therapeutics - the perfect catch-up trade. Tregs suppress other immune cells to shut down the immune response-for example, to prevent autoimmune disease-while helper T cells activate other immune cells. Unlike FLX475, which focuses on Tregs, the inflammation candidate RPT193 takes aim at helper T cells. Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. On average, analysts predict that RAPT Therapeutics will post -2.67 EPS for the current year. RELATED: Celgene, GV-backed FLX gets off $60M round, kick-starts I-O trials RAPT Therapeutics had a negative net margin of 1,468.46 and a negative return on equity of 41.61. “Since our founding, we have internally discovered and advanced two unique drug candidates that target CCR4, with FLX475 in development for the treatment of multiple cancers and RPT193 expected to enter clinical studies in the second half of 2019," Wong said. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant. But FLX, now RAPT, went in a different direction. 10, 2021 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. RELATED: FierceBiotech’s 2018 Fierce 15 | FLX BioĪt the time, the company planned to pick out a second clinical candidate targeting the enzyme ubiquitin specific protease 7 (USP7), which plays a role in two cancer pathways. RAPT Therapeutics Reports Third Quarter 2021 Financial Results.